{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:17:49Z","timestamp":1769721469408,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/maj.0b013e3181ae9227","type":"journal-article","created":{"date-parts":[[2009,11,10]],"date-time":"2009-11-10T08:16:16Z","timestamp":1257840976000},"page":"414-417","source":"Crossref","is-referenced-by-count":34,"title":["Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?"],"prefix":"10.1016","volume":"338","author":[{"given":"Mark","family":"Goldblatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Terrill","family":"Huggins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Doelken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puncho","family":"Gurung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Sahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0005","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2014a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0010","unstructured":"National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology TM: chronic myelogenous leukemia. Version 2.2010. Available at: www.nccn.org\/professionals\/physican_gls\/PDF\/cml.pdf."},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0015","doi-asserted-by":"crossref","first-page":"11a","DOI":"10.1182\/blood.V104.11.23.23","article-title":"Four years follow-up of 1027 patients with late chronic phase (CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials","volume":"104","author":"Silver","year":"2004","journal-title":"Blood"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0020","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS 358425 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0025","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0030","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1378\/chest.116.1.212","article-title":"Drug-induced pleural disease","volume":"116","author":"Morelock","year":"1999","journal-title":"Chest"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0272-5231(03)00125-4","article-title":"Drug-induced pleural disease","volume":"25","author":"Huggins","year":"2004","journal-title":"Clin Chest Med"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0040","series-title":"Drug-induced iatrogenic lung disease.","article-title":"Drug-induced pleural disease","author":"Sahn","year":"2009"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0272-5231(05)70080-0","article-title":"Drug-induced pleural disease","volume":"19","author":"Antony","year":"1998","journal-title":"Clin Chest Med"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0050","unstructured":"The drug-induced lung diseases. Available at: www.pneumotox.com."},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0055","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and- intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0060","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia a case series","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0065","first-page":"700","article-title":"The lipoprotein profile of chylous and nonchylous pleural effusions","volume":"55","author":"Staats","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/bjs.1800840107","article-title":"Chylothorax","volume":"84","author":"Merrigan","year":"1997","journal-title":"Br J Surg"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0075","series-title":"Sprycel, prescribing information","year":"2007"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0080","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccr.2004.08.034","article-title":"PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic vessel metastasis","volume":"6","author":"Cao","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1097\/MAJ.0b013e3181ae9227_bb0090","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1378\/chest.08-0137","article-title":"Yellow nail syndrome: Analysis of 41 consecutive patents","volume":"134","author":"Maldonado","year":"2008","journal-title":"Chest"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915317791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915317791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T14:54:02Z","timestamp":1590245642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915317791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0002962915317791"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3181ae9227","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}